The Intersection of Pulmonary Vascular Disease and Hypoxia-Inducible Factors

Madathilparambil V Suresh; Vikas Aggarwal; Krishnan Raghavendran

doi:10.1016/j.iccl.2023.03.010

The Intersection of Pulmonary Vascular Disease and Hypoxia-Inducible Factors

Interv Cardiol Clin. 2023 Jul;12(3):443-452. doi: 10.1016/j.iccl.2023.03.010. Epub 2023 Apr 28.

Authors

Madathilparambil V Suresh¹, Vikas Aggarwal², Krishnan Raghavendran³

Affiliations

¹ Division of Acute Care Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI, USA.
² Division of Cardiology (Frankel Cardiovascular Center), Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Section of Cardiology, Department of Internal Medicine, Veterans Affairs Medical Center, Ann Arbor, MI, USA.
³ Division of Acute Care Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI, USA. Electronic address: kraghave@umich.edu.

PMID: 37290846
DOI: 10.1016/j.iccl.2023.03.010

Abstract

Hypoxia-inducible factors (HIFs) are a family of nuclear transcription factors that serve as the master regulator of the adaptive response to hypoxia. In the lung, HIFs orchestrate multiple inflammatory pathways and signaling. They have been reported to have a major role in the initiation and progression of acute lung injury, chronic obstructive pulmonary disease, pulmonary fibrosis, and pulmonary hypertension. Although there seems to be a clear mechanistic role for both HIF 1α and 2α in pulmonary vascular diseases including PH, a successful translation into a definitive therapeutic modality has not been accomplished to date.

Keywords: HIF 1 alpha; Pulmonary hypertension; Pulmonary vascular disease.

Publication types

Review

MeSH terms

Basic Helix-Loop-Helix Transcription Factors* / metabolism
Humans
Hypertension, Pulmonary*
Hypoxia
Lung / metabolism

Substances

Basic Helix-Loop-Helix Transcription Factors